Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110032 · ClinicalTrials.gov registry record · Phase 1
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00110032: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00110032 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00110032, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects of fluorine F18 EF5 when given during positron emission tomography to find oxygen in tumor cells of patients who are undergoing surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18 EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer treatment
Interventions
- OTHER pharmacological study
- PROCEDURE positron emission tomography
- PROCEDURE conventional surgery
- DRUG EF5
- RADIATION fluorine F 18 EF5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110032
The ClinicalTrials.gov registry entry for NCT00110032 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00110032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110032 about?
NCT00110032 is a clinical study titled "Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors". This phase I trial is studying the side effects of fluorine F18 EF5 when given during positron emission tomography to find oxygen in tumor cells of patients who are undergoing surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18 EF5 and positron emission tomo...
What is the current status of trial NCT00110032?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2005-06.
What interventions are being tested in trial NCT00110032?
The interventions under investigation include: pharmacological study (OTHER), positron emission tomography (PROCEDURE), conventional surgery (PROCEDURE), EF5 (DRUG), fluorine F 18 EF5 (RADIATION).
Who is sponsoring clinical trial NCT00110032?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.